Human Genetics Society of Australasia Position Statement: Genetic Carrier Testing for Recessive Conditions.

Genetic testing carrier testing children ethics impaired capacity to consent

Journal

Twin research and human genetics : the official journal of the International Society for Twin Studies
ISSN: 1832-4274
Titre abrégé: Twin Res Hum Genet
Pays: England
ID NLM: 101244624

Informations de publication

Date de publication:
04 2023
Historique:
medline: 21 7 2023
pubmed: 25 5 2023
entrez: 25 5 2023
Statut: ppublish

Résumé

This Position Statement provides guidelines to assist all health professionals who receive requests for carrier testing and laboratory staff conducting the tests.In this Statement, the term 'carrier testing' refers to genetic testing in an individual to determine whether they have inherited a pathogenic variant associated with an autosomal or X-linked recessive condition previously identified in a blood relative. Carrier testing recommendations: (1) Carrier testing should only be performed with the individual's knowledge and consent; (2) An individual considering (for themselves, or on behalf of another) whether to have a carrier test should be supported to make an informed decision; (3) The mode of inheritance, the individual's personal experience with the condition, and the healthcare setting in which the test is being performed should be considered when determining whether carrier testing should be offered by a genetic health professional. Regarding children and young people: Unless there is direct medical benefit in the immediate future, the default position should be to postpone carrier testing until the child or young person can be supported to make an informed decision. There may be some specific situations where it is appropriate to facilitate carrier testing in children and young people (see section in this article). In such cases, testing should only be offered with pre- and post-test genetic counseling in which genetic health professionals and parents/guardians should explore the rationale for testing and the interests of the child and the family.

Identifiants

pubmed: 37226803
pii: S1832427423000154
doi: 10.1017/thg.2023.15
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

188-194

Auteurs

Danya F Vears (DF)

Biomedical Ethics Research Group, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
Center for Biomedical Ethics and Law, Department of Public Health and Primary Care, Leuven, Belgium.

Jackie Boyle (J)

Genetics of Learning Disability Service, Waratah, New South Wales, Australia.

Chris Jacobs (C)

Graduate School of Health, University of Technology Sydney, New South Wales, Australia.

Aideen McInerney-Leo (A)

Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.

Ainsley J Newson (AJ)

The University of Sydney, Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health Ethics, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH